Utility of positron emission tomography scans in mantle cell lymphoma

Peter Hosein, Vitor H. Pastorini, Fabio M. Paes, Daryl Eber, Jennifer Chapman-Fredricks, Aldo N Serafini, Ash A. Alizadeh, Izidore Lossos

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Positron emission tomography (PET) scans are widely used in patients with lymphoma but little is known about their utility in mantle cell lymphoma (MCL). MCL patients were included from two prospective trials and one observational study at our institution. A total of 276 PET scans were performed among 52 patients. After a median follow-up of 37.5 months, the 3-year event-free survival (EFS) and overall survival (OS) were 73% (95% confidence interval [CI]: 61-85%) and 92% (95% CI 85-100%), respectively. There were 34 pretreatment PET scans, 26 interim, 28 end-of-treatment, 162 surveillance, and 26 scans at relapse or beyond. Pretreatment PETs were positive in 94%. A negative interim or end-of-therapy PET scan was not significantly associated with better EFS or OS, but no deaths were observed in patients who had a negative interim or end-of-therapy PET. Surveillance PET scans had a high false positive rate (35%) and low positive predictive value (8%). PET scans contributed to an earlier diagnosis of relapse in only two out of the 18 patients (11%) who relapsed. PET scans did not meaningfully contribute to staging or surveillance of MCL patients in this study. There was a trend toward improved survival in patients who had a negative end-of-therapy PET scan.

Original languageEnglish
Pages (from-to)841-845
Number of pages5
JournalAmerican Journal of Hematology
Volume86
Issue number10
DOIs
StatePublished - Oct 1 2011

Fingerprint

Mantle-Cell Lymphoma
Positron-Emission Tomography
Disease-Free Survival
Survival
Confidence Intervals
Recurrence
Therapeutics
Observational Studies
Early Diagnosis
Lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Utility of positron emission tomography scans in mantle cell lymphoma. / Hosein, Peter; Pastorini, Vitor H.; Paes, Fabio M.; Eber, Daryl; Chapman-Fredricks, Jennifer; Serafini, Aldo N; Alizadeh, Ash A.; Lossos, Izidore.

In: American Journal of Hematology, Vol. 86, No. 10, 01.10.2011, p. 841-845.

Research output: Contribution to journalArticle

Hosein, Peter ; Pastorini, Vitor H. ; Paes, Fabio M. ; Eber, Daryl ; Chapman-Fredricks, Jennifer ; Serafini, Aldo N ; Alizadeh, Ash A. ; Lossos, Izidore. / Utility of positron emission tomography scans in mantle cell lymphoma. In: American Journal of Hematology. 2011 ; Vol. 86, No. 10. pp. 841-845.
@article{d2d6b2aec57f47a7ae0426ea8892ea33,
title = "Utility of positron emission tomography scans in mantle cell lymphoma",
abstract = "Positron emission tomography (PET) scans are widely used in patients with lymphoma but little is known about their utility in mantle cell lymphoma (MCL). MCL patients were included from two prospective trials and one observational study at our institution. A total of 276 PET scans were performed among 52 patients. After a median follow-up of 37.5 months, the 3-year event-free survival (EFS) and overall survival (OS) were 73{\%} (95{\%} confidence interval [CI]: 61-85{\%}) and 92{\%} (95{\%} CI 85-100{\%}), respectively. There were 34 pretreatment PET scans, 26 interim, 28 end-of-treatment, 162 surveillance, and 26 scans at relapse or beyond. Pretreatment PETs were positive in 94{\%}. A negative interim or end-of-therapy PET scan was not significantly associated with better EFS or OS, but no deaths were observed in patients who had a negative interim or end-of-therapy PET. Surveillance PET scans had a high false positive rate (35{\%}) and low positive predictive value (8{\%}). PET scans contributed to an earlier diagnosis of relapse in only two out of the 18 patients (11{\%}) who relapsed. PET scans did not meaningfully contribute to staging or surveillance of MCL patients in this study. There was a trend toward improved survival in patients who had a negative end-of-therapy PET scan.",
author = "Peter Hosein and Pastorini, {Vitor H.} and Paes, {Fabio M.} and Daryl Eber and Jennifer Chapman-Fredricks and Serafini, {Aldo N} and Alizadeh, {Ash A.} and Izidore Lossos",
year = "2011",
month = "10",
day = "1",
doi = "10.1002/ajh.22126",
language = "English",
volume = "86",
pages = "841--845",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "10",

}

TY - JOUR

T1 - Utility of positron emission tomography scans in mantle cell lymphoma

AU - Hosein, Peter

AU - Pastorini, Vitor H.

AU - Paes, Fabio M.

AU - Eber, Daryl

AU - Chapman-Fredricks, Jennifer

AU - Serafini, Aldo N

AU - Alizadeh, Ash A.

AU - Lossos, Izidore

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Positron emission tomography (PET) scans are widely used in patients with lymphoma but little is known about their utility in mantle cell lymphoma (MCL). MCL patients were included from two prospective trials and one observational study at our institution. A total of 276 PET scans were performed among 52 patients. After a median follow-up of 37.5 months, the 3-year event-free survival (EFS) and overall survival (OS) were 73% (95% confidence interval [CI]: 61-85%) and 92% (95% CI 85-100%), respectively. There were 34 pretreatment PET scans, 26 interim, 28 end-of-treatment, 162 surveillance, and 26 scans at relapse or beyond. Pretreatment PETs were positive in 94%. A negative interim or end-of-therapy PET scan was not significantly associated with better EFS or OS, but no deaths were observed in patients who had a negative interim or end-of-therapy PET. Surveillance PET scans had a high false positive rate (35%) and low positive predictive value (8%). PET scans contributed to an earlier diagnosis of relapse in only two out of the 18 patients (11%) who relapsed. PET scans did not meaningfully contribute to staging or surveillance of MCL patients in this study. There was a trend toward improved survival in patients who had a negative end-of-therapy PET scan.

AB - Positron emission tomography (PET) scans are widely used in patients with lymphoma but little is known about their utility in mantle cell lymphoma (MCL). MCL patients were included from two prospective trials and one observational study at our institution. A total of 276 PET scans were performed among 52 patients. After a median follow-up of 37.5 months, the 3-year event-free survival (EFS) and overall survival (OS) were 73% (95% confidence interval [CI]: 61-85%) and 92% (95% CI 85-100%), respectively. There were 34 pretreatment PET scans, 26 interim, 28 end-of-treatment, 162 surveillance, and 26 scans at relapse or beyond. Pretreatment PETs were positive in 94%. A negative interim or end-of-therapy PET scan was not significantly associated with better EFS or OS, but no deaths were observed in patients who had a negative interim or end-of-therapy PET. Surveillance PET scans had a high false positive rate (35%) and low positive predictive value (8%). PET scans contributed to an earlier diagnosis of relapse in only two out of the 18 patients (11%) who relapsed. PET scans did not meaningfully contribute to staging or surveillance of MCL patients in this study. There was a trend toward improved survival in patients who had a negative end-of-therapy PET scan.

UR - http://www.scopus.com/inward/record.url?scp=84860392642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860392642&partnerID=8YFLogxK

U2 - 10.1002/ajh.22126

DO - 10.1002/ajh.22126

M3 - Article

VL - 86

SP - 841

EP - 845

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 10

ER -